Volume 1, Issue 2
Editorialp. 181
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Author(s): Blair Henry, Yulia Lin, Jeannie Callum
Therapeutic Prospectivep. 195
Strategies to treat sepsis: old and new
Author(s): Steven P LaRosa, Steven M Opal
Therapeutic Prospectivep. 211
Development of antibiotics for Gram-negatives: where now?
Author(s): Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospectivep. 229
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Author(s): Brian Lam,Zobair M Younossi
Review Articlep. 241
Tyrosine kinase inhibitors in differentiated thyroid arcinoma: a review of the clinical evidence
Author(s): Hendrieke C Hoftijzer, Ellen Kapiteijn2, Tatiana, Schneider, Guido C Hovens, Hans Morreau, Hans Gelderblom, Johannes WA Smit
Review Articlep. 255
Emerging treatments for small-cell lung cancer: Phase II and III trials
Author(s): Joel W Neal, Matthew A Gubens, Heather A Wakelee
Review Articlep. 265
Diagnosis and treatment of prostate cancer-related bone disease
Author(s): Tilman Todenhoefer, Georgios Gakis, David Schilling, Gerhard Feil, Christian Schwentner,Arnulf Stenzl
Review Articlep. 285
Velaglucerase alfa in the treatment of Gaucher disease type 1
Author(s): Thomas A Burrow, Gregory A Grabowski
Review Articlep. 295
Eltrombopag for the treatment of chronic immune thrombocytopenia
Author(s): Stavroula Tsiara, Nichola Cooper
Review Articlep. 305
Clinical efficacy and safety of moroctocog alfa
Author(s): Emanuela Marchesini, Domenico Prisco, Alfonso Iorio
Review Articlep. 317
Cladribine in the treatment of multiple sclerosis
Author(s): Karen Schreiber, Per Soelberg Sorensen
Review Articlep. 327
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Author(s): Marta Letizia Hribal, Giorgio Sesti
Review Articlep. 345
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Author(s): Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
Acknowledgementsp. 355
Acknowledgements: Clinical Investigation Vol 1, No 2
Editor\\\'s Notep. 357-358
